[TKI Resistance for T790M Mutation].

about

Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.

P2860

Q37666880-1D022EC2-7C0A-48E2-87FC-E240FA6105CE

P2860

[TKI Resistance for T790M Mutation].

Item

http://www.wikidata.org/entity/Q54274283

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

[TKI Resistance for T790M Mutation].

@en

[TKI Resistance for T790M Mutation].

@nl

type

Item

label

[TKI Resistance for T790M Mutation].

@en

[TKI Resistance for T790M Mutation].

@nl

prefLabel

[TKI Resistance for T790M Mutation].

@en

[TKI Resistance for T790M Mutation].

@nl

P1476

[TKI Resistance for T790M Mutation].

@en

P2093

Hong Wang

http://www.w3.org/2001/XMLSchema#string

Liyu Zhang

http://www.w3.org/2001/XMLSchema#string

Rui Guo

http://www.w3.org/2001/XMLSchema#string

P2860

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

P304

245-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3779/J.ISSN.1009-3419.2015.04.10

http://www.w3.org/2001/XMLSchema#string

P407

Chinese

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25936890

http://www.w3.org/2001/XMLSchema#string

P932

6000286

http://www.w3.org/2001/XMLSchema#string

[TKI Resistance for T790M Mutation].

about

P2860

P2860

[TKI Resistance for T790M Mutation].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932